Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

If P&G Seeks OTC Sale, Pharma Buyers Might Line Up

Fri, 06/23/2017 - 6:56pm

P&G's activist investor Trian Fund Management is known for pressuring big companies to break up. The OTC business would likely...

      Related Stories 

Pfizer, Cipla Pledge Better Access To Affordable Cancer Therapies In Africa

Fri, 06/23/2017 - 9:18am

Pfizer and Cipla have separately committed to expanding access to affordable oncology drugs in sub-Saharan Africa in collaboration with the...

      Related Stories 

EU CHMP OKs Imraldi, Samsung Bioepis’ Biosimilar Of AbbVie’s Humira

Fri, 06/23/2017 - 9:08am

The EU’s CHMP has given the green light to Imraldi, Samsung Bioepis’ biosimilar version of AbbVie’s blockbuster adalimumab product Humira...

      Related Stories 

CHMP OK Puts Merck KGaA's Cladribine Pill On EU Home Stretch After Long Trek

Fri, 06/23/2017 - 8:54am

Merck of Germany's oral multiple sclerosis medicine cladribine looks set to finally get EU approval. But the long, slow race...

      Related Stories 

Pipeline Watch: Top-Line Phase III Canakinumab, Shingrix And Brolucizumab Readouts

Fri, 06/23/2017 - 8:46am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Novartis' Kisqali CHMP Nod In Fast-Moving Market

Fri, 06/23/2017 - 8:36am

The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer...

      Related Stories 

Novartis' Kisqali CHMP Nod In Fast-Moving Market

Fri, 06/23/2017 - 8:36am

The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer...

      Related Stories 

Lifted Regulatory Overhang Raises Cadila’s Value

Thu, 06/22/2017 - 11:28pm

Cadila Healthcare, the listed flagship of billionaire Pankaj Patel’s Zydus Group, has become India’s second most valuable pharmaceutical firm after...

      Related Stories 

Asia Executives To Watch: New FDA China Director Named Amid ICH Push

Thu, 06/22/2017 - 6:48pm

The US FDA has sent its country director from Peru to build a closer relationship with the China FDA, while...

      Related Stories 

Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?

Thu, 06/22/2017 - 3:16pm

NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas...

      Related Stories 

Melinta To Launch First Commercial Drug Baxdela Independently

Thu, 06/22/2017 - 12:34pm

Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but...

      Related Stories 

CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron

Thu, 06/22/2017 - 9:00am

Few expected the positive top-line results from CANTOS showing the Phase III cardiovascular disease study using canakinumab met the primary...

      Related Stories 

CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron

Thu, 06/22/2017 - 9:00am

Few expected the positive top-line results from CANTOS showing the Phase III cardiovascular disease study using canakinumab met the primary...

      Related Stories 

EU’s CHMP Expected To OK Another Biosimilar Humira

Thu, 06/22/2017 - 7:50am

The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha...

      Related Stories 

BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy

Wed, 06/21/2017 - 10:59pm

Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as...

      Related Stories 

Pages